Biovica International AB Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Congrats to the recent developments here. So first of all, if I've understood things correctly, looking at the commercialization side here, you've indicated that that you, in the longer term, could enter an agreement with a larger commercial partner or perhaps several lab partners in the U.s., is this correct? And what do you expect you need to get in place before expanding your commercial footprint in the U.S., would it be broader guideline inclusions or reimbursement coverage? Or what steps should we expect for you to expand that commercial presence in the U.S., if you will? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 08, 2020 / 9:00AM, BIOVICb.ST - Q2 2021 Biovica International AB Earnings Call

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Yes, of course. And just as a clarification there. In terms of these lab partners, are they usually keen on getting exclusivity? Or is it a trade-off between sort of a revenue split, if you will, that they are willing to leave exclusivity open? Do you understand a bit what I'm looking for in terms of their terms in the agreement, yes?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Great. And just looking at the case load of COVID-19 cases in the U.S. and the continued rush here for testing applications. Are you seeing any worries that your 90-days FDA delay could be extended? Or how should we think about that potential risk on the timeline?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Great. Great. Sounds promising. And just a final question here on the prognostic use case and particularly looking at the abstracts here from the San Antonio Breast Cancer Symposium. Isn't it usually the case that patient response is poorer in a faster-growing tumor versus a slower growing tumor, i.e., that TK1 sort of at baseline answers and already clear question in terms of a prediction of outcome in the patients so that, i.e., a higher TK 1 activity sort of per definition leads to a poorer response? So how should we think about the prognostic use case data?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Sure. Great. And just final there on the prognostic. Do you think that the prognostic use case will require larger prospective and mortality based outcome studies to reach guideline inclusion and uptake? Or do you think that other endpoints such as progression and these types of endpoints are enough, if you will, to gain traction and uptake in that sort of use case?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : No, basically, just in terms of getting guideline inclusion and broader uptake, if you believe that larger prospective trials, which look at mortality will be needed to reach guideline inclusion and commercial uptake and they are covered from the insurance companies and so forth?

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Yes, sure.

Question: Rickard Anderkrans - ABG Sundal Collier Introduce - Analyst : Sure, sure. Right. So that might be a few years from right now? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 08, 2020 / 9:00AM, BIOVICb.ST - Q2 2021 Biovica International AB Earnings Call